Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

Redmile Group increased its Nurix Therapeutics holding by 4,415,514 shares; the estimated trade value was $63.43 million based on quarterly average pricing. Meanwhile, the quarter-end position value rose by $119.55 million, reflecting the combined impact of share purchases and Nurix Therapeutics' price movement.

The Motley Fool • Feb 22, 2026

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile in relapsed/refractory CLL 83% objective overall response rate and progression free survival of 22.1 months demonstrate durable therapeutic effects in a large portion of patients Presented differentiated preclinical data for IRAK4 degrader GS-6791 in collaboration with Gilead Well capitalized with cash and marketable securities of $592.9 million BRISBANE, Australia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today reported financial results for the fiscal quarter ended November 30, 2025, and highlighted significant progress across its clinical programs and strategic collaborations. “The fourth quarter marked a pivotal inflection point for Nurix as we initiated the DAYBreak™ registrational program for bexobrutideg and strengthened our balance sheet to support execution across our pipeline,” said Arthur T.

GlobeNewsWire • Jan 28, 2026

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.75 per share a year ago.

Zacks Investment Research • Jan 28, 2026

Nurix Therapeutics: Why This Company Could Double In Value?

Nurix Therapeutics is positioned for a breakthrough in CLL with NX-5948, demonstrating strong efficacy in post-Pirtobrutinib settings. Phase 1 data showed an 83% response rate at 600mg and 22.1 months of progression-free survival, enabling direct advancement to phase 3 trials. NRIX holds $680M in cash, supporting R&D through 2027-2028 and minimizing dilution risk for shareholders.

Seeking Alpha • Jan 16, 2026

Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)

GlobeNewsWire • Jan 12, 2026

Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside

Nurix Therapeutics offers a compelling risk/reward profile, driven by bexobrutideg's superior efficacy in B-cell malignancies versus current therapies. NRIX's strong cash position—over $650 million—funds operations through 2028, supporting aggressive R&D and pivotal trial advancement. Bexobrutideg's unique BTK degradation mechanism delivers longer progression-free survival and CNS activity, addressing critical unmet needs in relapsed/refractory patients.

Seeking Alpha • Jan 12, 2026

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T.

GlobeNewsWire • Jan 5, 2026

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript

Seeking Alpha • Dec 9, 2025

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of response (DOR) and median progression-free survival (PFS) have not been reached Encouraging efficacy and favorable tolerability support continued development of bexobrutideg in Waldenström macroglobulinemia Nurix will host a webcast to discuss the data presented at the ASH Annual Meeting and provide a corporate update today at 8:15 p.m. ET BRISBANE, Calif.

GlobeNewsWire • Dec 8, 2025